Research programme: RNA interference-based technology - Alnylam

Drug Profile

Research programme: RNA interference-based technology - Alnylam

Alternative Names: KC2; MC3; MC3 LNP; MD1; reLNP

Latest Information Update: 14 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer AlCana Technologies; Alnylam Pharmaceuticals; Icahn School of Medicine at Mount Sinai; Massachusetts General Hospital; Massachusetts Institute of Technology; University of Bonn; University of British Columbia
  • Class Small interfering RNA
  • Mechanism of Action CCR2 receptor antagonists; Claudin 3 inhibitors; DNA-directed RNA polymerase inhibitors; RNA interference; TOR1A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Autoimmune disorders; Cancer; Dystonia; Inflammation; Influenza A virus infections

Most Recent Events

  • 17 Jan 2013 No development reported - Preclinical for Cancer in Germany (Parenteral)
  • 16 Jan 2013 Preclinical trials in Autoimmune disorders in USA (Parenteral)
  • 12 Nov 2012 Alnylam Pharmaceuticals and Tekmira Pharmaceuticals Corporation sign a new licensing agreement regarding RNAi-based therapies, superseding all previous agreements, and resolve all litigation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top